Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.

Samizadeh M, Zhang X, Gunaseelan S, Nelson AG, Palombo MS, Myers DR, Singh Y, Ganapathi U, Szekely Z, Sinko PJ.

Drug Deliv Transl Res. 2016 Feb;6(1):1-16. doi: 10.1007/s13346-015-0269-4.

2.

The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.

Seay K, Khajoueinejad N, Zheng JH, Kiser P, Ochsenbauer C, Kappes JC, Herold B, Goldstein H.

J Virol. 2015 Sep;89(18):9559-70. doi: 10.1128/JVI.01326-15. Epub 2015 Jul 8.

3.

Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.

Havens PL, Hazra R.

Pediatr Infect Dis J. 2015 Apr;34(4):406-8. doi: 10.1097/INF.0000000000000650. No abstract available.

4.

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Baheti G, King JR, Acosta EP, Fletcher CV.

AIDS. 2013 Jan 14;27(2):221-5. doi: 10.1097/QAD.0b013e32835a9a2d.

5.

New approaches in the management of chronic hepatitis B: role of tenofovir.

Reijnders JG, LA Janssen H.

Infect Drug Resist. 2009;2:13-26. Epub 2009 Apr 24.

6.

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP; P1058 Protocol Team.

Antimicrob Agents Chemother. 2011 Sep;55(9):4290-4. doi: 10.1128/AAC.01334-10. Epub 2011 Jun 13.

7.

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R.

J Pediatr. 2008 Apr;152(4):582-4. doi: 10.1016/j.jpeds.2007.12.020.

8.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions.

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

Supplemental Content

Support Center